Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML
Conditions
Interventions
NTX-301
Locations
2
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Start Date
January 6, 2021
Primary Completion Date
March 31, 2026
Completion Date
March 31, 2026
Last Updated
September 24, 2025
NCT06303193
NCT05564390
NCT03050268
NCT07320235
NCT06847867
NCT06782542
Lead Sponsor
University of Alabama at Birmingham
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions